Soft Tissue Sarcoma: The Important Role of Initial MRI Reports for Disease Control

2020 ◽  
Author(s):  
S Weiß ◽  
A Korthaus ◽  
K-H Frosch ◽  
C Schlickewei ◽  
M Priemel
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Disease Control

Role of centers with different patient volumes in the management of rhabdomyosarcoma. An analysis by the Italian Pediatric Soft Tissue Sarcoma Committee

2021 ◽  
Author(s):  
Gianni Bisogno ◽  
Giovanna Congiu ◽  
Maria Carmen Affinita ◽  
Giuseppe Maria Milano ◽  
Ilaria Zanetti ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma

scholarly journals Role of Matrix Metalloproteinase (MMP) 2 and MMP-9 in Soft Tissue Sarcoma

2014 ◽  
Vol 6 (4) ◽  
pp. 443 ◽  
Author(s):  
Hyun Kee Yang ◽  
Kwang Cheul Jeong ◽  
Yang Kyung Kim ◽  
Sung Taek Jung
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Matrix Metalloproteinase

scholarly journals 1550P A post hoc analysis of the EPAZ trial: The prognostic role of geriatric variables in elderly soft tissue sarcoma (STS) patients

2021 ◽  
Vol 32 ◽  
pp. S1125-S1126
Author(s):  
R.W. Hamacher ◽  
X. Liu ◽  
M.K. Schuler ◽  
L. Hentschel ◽  
P. Schöffski ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Prognostic Role ◽  
Post Hoc Analysis ◽  
Post Hoc

Adjuvant role of radiation in soft tissue sarcoma in adults

1977 ◽  
Vol 9 (4) ◽  
pp. 329-338 ◽  
Author(s):  
Brace L. Hintz ◽  
Komanduri K. N. Charyulu ◽  
Wallace E. Miller ◽  
Anam Sudarsanam
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma

The role of 18F-FDG PET/CT in soft tissue sarcoma

2019 ◽  
Vol 40 (6) ◽  
pp. 626-631 ◽  
Author(s):  
Andrea Sambri ◽  
Giuseppe Bianchi ◽  
Alessandra Longhi ◽  
Alberto Righi ◽  
Davide Maria Donati ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Fdg Pet ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Single arm prospective study evaluating the role of neoadjuvant chemotherapy in soft tissue sarcoma

2018 ◽  
Vol 29 ◽  
pp. viii585
Author(s):  
A. Tiwari ◽  
S. Rastogi ◽  
S.V.S. Deo ◽  
D.N. Sharma ◽  
M.C. Sharma ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Neoadjuvant Chemotherapy ◽  
Soft Tissue Sarcoma ◽  
Prospective Study

Role of compartmental resection for soft tissue sarcoma of the limb and limb girdle

1990 ◽  
Vol 77 (1) ◽  
pp. 88-92 ◽  
Author(s):  
A. Stotter ◽  
M. Fallowfield ◽  
A. Mott ◽  
C. Fisher ◽  
G. Westbury
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Compartmental Resection

scholarly journals Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma

Sarcoma ◽  
2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Christopher L. Tinkle ◽  
Vivian Weinberg ◽  
Steve E. Braunstein ◽  
Rosanna Wustrack ◽  
Andrew Horvai ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Disease Control ◽  
Local Control ◽  
Intraoperative Radiotherapy ◽  
Disease Free Survival ◽  
Median Dose ◽  
Extremity Soft Tissue Sarcoma ◽  
Locally Recurrent ◽  
Grade 3

Purpose. To investigate the efficacy and morbidity of limb-sparing surgery with intraoperative radiotherapy (IORT) for patients with locally recurrent extremity soft tissue sarcoma (ESTS).Methods and Materials. Twenty-six consecutively treated patients were identified in a single institution retrospective analysis of patients with locally recurrent ESTS treated with IORT following salvage limb-sparing resection from May 2000 to July 2011. Fifteen (58%) patients received external beam radiotherapy (EBRT) prior to recurrence (median dose 63 Gy), while 11 (42%) patients received EBRT following IORT (median dose 52 Gy). The Kaplan-Meier product limit method was used to estimate disease control and survival and subsets were compared using a log rank statistic, Cox’s regression model was used to determine independent predictors of disease outcome, and toxicity was reported according to CTCAE v4.0 guidelines.Results. With a median duration of follow-up from surgery and IORT of 34.9 months (range: 4 to 139 mos.), 10 patients developed a local recurrence with 4 subsequently undergoing amputation. The 5-year estimate for local control (LC) was 58% (95% CI: 36–75%), for amputation-free was 81% (95% CI: 57–93%), for metastasis-free control (MFC) was 56% (95% CI: 31–75%), for disease-free survival (DFS) was 35% (95% CI: 17–54%), and for overall survival (OS) was 50% (95% CI: 24–71%). Prior EBRT did not appear to influence disease control (LC,p=0.74; MFC,p=0.66) or survival (DFS,p=0.16; OS,p=0.58). Grade 3 or higher acute and late toxicities were reported for 6 (23%) and 8 (31%) patients, respectively. The frequency of both acute and late grade 3 or higher toxicities occurred equally between patients who received EBRT prior to or after IORT.Conclusions. IORT in combination with oncologic resection of recurrent ESTS yields good rates of local control and limb-salvage with acceptable morbidity. Within the limitations of small subsets, these data suggest that prior EBRT does not significantly influence disease control or toxicity.

Sign in / Sign up

Export Citation Format

Share Document